Background: Estimation of Quality of life is a useful outcome measure to know about epilepsy care from patient’s perspective. Assessing QOL of epileptic patients is important so as to manage the epilepsy and to implement some interventional programs in order to improve the quality of life of these patients. The study aims to find out the impact of epilepsy on quality of life of epileptic patients Material and method: This was a cross-sectional, questionnaire-based study, conducted from March to August 2019 for a period of 6 months, after approval from Institutional Ethics Committee. Data was analyzed using Statistical Package for Social Sciences (SPSS) version 25. The quality of life in epilepsy (QOLIE-31) was used for collecting data on health-related QOL. Result: The study group consisted of 65 patients of whom 48 were males (73.84%) and 17 were females (26.15%). Their ages ranged from 19 to 60 years. (mean age: 35.65). Majority of the patients were in the age range of 30-41 (40%). 50.8% participants were from nuclear family and 49.2% were from joint family system. Most of the patients had lower class socioeconomic status (61.5%). As regard to the employment status, 38.4% of patients were full time employed, 13.8% were part time employed. 29.2% were unemployed and 9.23% were retired and 9.23% were students.  The medication analysis revealed that 30.6% of the participants were on monotherapy whereas 69.0% were on polytherapy. The mean total QOLIE-31 score was 39.12 (SD-5.00). Conclusion: Epileptic patients had poor QOL with low total QOLIE-31 score, unemployment, use of combination therapy and people belonging to lower class were associated with lower quality of life in individuals with epilepsy. Keywords: Health Related Quality of life, Epilepsy, Quality of Life in Epilepsy (QOLIE-31) questionnaire

Alzheimer's disease (AD) is a neurodegenerative disorder with relevant unmet therapeutic needs. Both natural aging and AD have been associated with a significant decline in the Omega-3 polyunsaturated fatty acid, docosahexaenoic acid (DHA), and accordingly, administration of DHA has been proposed as a possible treatment for this pathology. DHA and its derivatives like 2-hydroxy DHA-(OHDHA) have a strong therapeutic potential to treat AD. Studies have demonstrated that DHA induced lipid modifications are paralleled with a reduction in amyloid-beta (Αβ) accumulation and full recovery of cognitive impairment. Omega-3 fatty acids also caused alterations in the subcellular distribution of secretases and reduced Αβ-induced tau protein phosphorylation as well. Furthermore, OHDHA enhanced the survival of neuron-like differentiated cells exposed to different insults such as oligomeric Αβ and N-methyl-D-aspartate-mediated neurotoxicity. In conclusion, this review focuses on the pleiotropic effects of Omega-3 fatty acids that might prove beneficial to treat AD.

Background: Endothelial cells concerned in modulating vascular tone and structure. Endothelial plays an important role in homeostasis of the body and its dysfunction is correlated with numerous pathophysiology circumstances like diabetes, atherosclerosis. Patients with diabetes at all times show an impairment of endothelium-dependent vasodilation. Hyperglycaemia is the key aspect which develops the endothelial dysfunction in diabetes mellitus. Objective: The present study was aimed to investigate the activity of Dapagliflozin to reduce the risk of endothelial dysfunction associated with diabetes.Type 2 diabetes was induced by a single intraperitoneal Materials and Methods: injection of STZ (65mg/kg) + NAD (235mg/kg).After the administration of Streptozotocin (STZ) the animal showed marked hyperglycemia. Metformin and Captopril used as the standard drugs and the test drug Dapagliflozin administered for 28 days after the induction of endothelial dysfunction.After 28 days of treatment with Results: Dapagliflozin (10,20mg/kg) showed significant reduction in glucose level, glutathione level and improvement in lipid profiles. The treatment showed significant increase in body weight as compared to diabetic control and diabetes + endothelial dysfunction group.In the present study investigation, the activity of Dapagliflozin not only Conclusion: reduces the diabetes but also found to reduce the risk of endothelial dysfunction associated with diabetes.

Type II diabetes (T2DM) is caused by environmental, genetic, metabolic, and unknown variables. In diabetics, insulin resistance is the most of prolonged hyperglycemia. T2DM is induced by insulin resistance and cell dysfunction. The interaction of genetics and environment further complicates T2DM development. Insulin resistance and beta cell dysfunction are two of the most common Type 2 Diabetes Mellitus symptoms. A vicious triangle of cell failure (80% cell function) and insulin resistance in the muscles and liver causes major physiological issues. A group of diabetes patients (Group I), non-diabetic first-degree relatives of diabetic patients (Group II), and a non-diabetic healthy control group (Group III) were studied. The diabetes patients had the greatest systolic and diastolic blood pressures, followed by first degree relatives and healthy controls. We found that people with diabetes had higher fasting (FBS) and postprandial sugar, glycated haemoglobin (HbA1c) than diabetic offsprings and control group. Moreover, fasting insulin levels are higher in first degree relatives than in diabetes patients in the control group. The HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) levels of diabetics and their progeny do not differ much. The HOMA-IR measures insulin resistance severity. Common reference levels for HOMA-IR insulin resistance range from 0.7 - 2. Insulin resistance in diabetics and their first-degree relatives is evident from the results.